Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "SEC"

2406 News Found

Venus Remedies secures Ukrainian GMP renewal
News | May 23, 2025

Venus Remedies secures Ukrainian GMP renewal

Certification bolsters Venus Remedies' position in PIC/S markets, reinforcing commitment to global quality standards


Remedium Lifecare secures Rs. 182.7 crore export deal
News | May 16, 2025

Remedium Lifecare secures Rs. 182.7 crore export deal

The CDMO upgrade represents a transformational step for Remedium Lifecare


Biocon Biologics secures strong market coverage for Yesintek in US
News | May 05, 2025

Biocon Biologics secures strong market coverage for Yesintek in US

Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025


WHO prequalifies Syngenta’s innovative insecticide Sovrenta
News | April 23, 2025

WHO prequalifies Syngenta’s innovative insecticide Sovrenta

A new weapon in the global fight against malaria


Biocon Biologics secures market entry date for Yesafili in US
News | April 15, 2025

Biocon Biologics secures market entry date for Yesafili in US

YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions


Nureca’s manufacturing subsidiary secures USFDA registration
News | April 14, 2025

Nureca’s manufacturing subsidiary secures USFDA registration

This registration authorizes Nureca Technologies to continue manufacturing and exporting asuite of medical devices to the United States


Fredun secures tender from TNMSC for supply of generic pharma products
News | April 14, 2025

Fredun secures tender from TNMSC for supply of generic pharma products

The supply of these goods is set to commence within the first quarter of FY26


OneSource secures GMP approval from Brazil for its flagship facility in Bengaluru
Drug Approval | April 11, 2025

OneSource secures GMP approval from Brazil for its flagship facility in Bengaluru

This approval marks a significant milestone in OneSource’s ongoing commitment to quality and regulatory compliance


Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s
Drug Approval | April 09, 2025

Shilpa’s Unit-2 passes second consecutive FDA inspection with no 483s

Raichur site is the group’s largest API facility and part of a wider network of seven sites